Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery

Pharmaceutical Development and Technology

Volumn 21, Issue 2, 2016, Pages 172-179

  Duxfield, Linda ^a   Sultana, Rubab ^a   Wang, Ruokai ^a   Englebretsen, Vanessa ^a   Deo, Samantha ^a   Swift, Simon ^a   Rupenthal, Ilva ^a   Al Kassas, Raida ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Eudragit; gatifloxacin; nanoparticles; ocular drug delivery

Indexed keywords

CHLORMETHINE; CIPROFLOXACIN; CYCLODEXTRIN; EUDRAGIT; GATIFLOXACIN; NANOPARTICLE; POLYGLACTIN; POLYSORBATE 80; ANTIINFECTIVE AGENT; CATION; EMULSION; POLYMER; POLYSORBATE; QUINOLONE DERIVATIVE; SURFACTANT;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMULSION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NANOEMULSION; NANOPRECIPITATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; PRECIPITATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY; SLOW DRUG RELEASE; STAPHYLOCOCCUS AUREUS; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; BACTERIUM; BIOAVAILABILITY; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; EYE; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES;

ANTI-INFECTIVE AGENTS; BACTERIA; BIOLOGICAL AVAILABILITY; CATIONS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; EMULSIONS; EYE; FLUOROQUINOLONES; HUMANS; NANOPARTICLES; PARTICLE SIZE; POLYMERS; POLYSORBATES; SURFACE-ACTIVE AGENTS;

EID: 84955699906     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2015.1091839     Document Type: Article

References (46)

1. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112: 466-469.
2. Fung-Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000;45:437-446.
3. Kaliamurthy J, Nelson CA, Geraldine P, et al. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res 2005;37:117-122.
4. Schultz C. Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective. Ophthalmol Eye Dis 2012;4:65.
5. Pawar P, Katara R, Mishra S, Majumdar DK. Topical ocular delivery of fluoroquinolones. Expert Opin Drug Deliv 2013;10:691-711.
6. Al-Abdullah ES. Gatifloxacin. Profiles of drug substances, excipients and related methodology. Milford, NJ: Academic Press; 2012:183-243.
7. Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. Curr Drug Deliv 2006;3:207-217.
8. Patel HA, Patel JK, Patel KN, Patel RR. Ophthalmic drug delivery system - a review. Der Pharmacia Lett 2010;2:100-115.
9. Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm 2006;314:72-82.
10. Bu HZ, Gukasyan HJ, Goulet L, et al. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 2007;8:91-107.
11. Del Pozo-Rodríguez A, Delgado D, Gascón AR, Solinís MA. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther 2013;29:173-188.
12. Rajendran N, Natrajan R, Kumar R, Selvaraj S. Acyclovir-loaded chitosan nanoparticles for ocular delivery. Asian J Pharm 2010; 4:220.
13. Sezer AD, Cevher E. Topical drug delivery using chitosan nano-and microparticles. Expert Opin Drug Deliv 2012;9:1129-1146.
14. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008;68:513-525.
15. Rong X, Xie Y, Hao X, et al. Applications of polymeric nanocapsules in field of drug delivery systems. Curr Drug Discov Technol 2011;8:173-187.
16. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009;26: 1025-1058.
17. Lee EJ, Khan SA, Park JK, Lim KH. Studies on the characteristics of drug-loaded gelatin nanoparticles prepared by nanoprecipitation. Bioprocess Biosyst Eng 2012;35:297-307.
18. Devarajan PV, Sonavane GS. Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers. Drug Dev Ind Pharm 2007;33:101-111.
19. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery. J Microencapsul 2011;28:37-45.
20. Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine 2010;6:318-323.
21. Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/ prednisolone bitherapy. Mol Pharm 2010;7:576-585.
22. Loveymi BD, Jelvehgari M, Zakeri-Milani P, Valizadeh H. Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability. Adv Pharm Bull 2012;2:43-56.
23. Jiang B, Hu L, Gao C, Shen J. Ibuprofen-loaded nanoparticles prepared by a co-precipitation method and their release properties. Int J Pharm 2005;304:220-230.
24. Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002;16:53-61.
25. Ceulemans J, Ludwig A. Optimisation of carbomer viscous eye drops: an in vitro experimental design approach using rheological techniques. Eur J Pharm Biopharm 2002;54:41-50.
26. Herrera LC, Tesoriero MVD, Hermida LG, et al. In vitro release testing of PLGA microspheres with Franz diffusion cells. Vitro 2012;19:6-11.
27. Ghosh B, Ramamoorthy D. Effects of Silver nanoparticles on Escherichia coli and it's implications. Int J Chem Sci 2010;8:31-40.
28. Lkhagvajav N, Yasa I, Celik E, et al. Antimicrobial activity of colloidal silver nanoparticles prepared by sol-gel method. Digest J Nanomater Biostruct 2011;6:149-154.
29. Leroux J, Allémann E, De Jaeghere F, et al. Biodegradable nanoparticles - from sustained release formulations to improved site specific drug delivery. J Control Release 1996;39:339-350.
30. Guhagarkar SA, Malshe VC, Devarajan PV. Nanoparticles of polyethylene sebacate: a new biodegradable polymer. AAPS PharmSciTech 2009;10:935-942.
31. Katara R, Majumdar DK. Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery. Colloids Surf B Biointerfaces 2013;103:455-462.
32. Pignatello R, Bucolo C, Spedalieri G, et al. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002;23:3247-3255.
33. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target 2004;12:623-633.
34. De Campos AM, Sánchez A, Gref R, et al. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003;20:73-81.
35. Instruments M. Zeta potential: an introduction in 30 minutes. Zetasizer Nano Serles Technical Note. MRK654-01 2011.
36. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech 2011;12:1087-1101.
37. McCarron P, Woolfson AD, Keating SM. Sustained release of 5-fluorouracil from polymeric nanoparticles. J Pharm Pharmacol 2000;52:1451-1459.
38. Schmidt C, Bodmeier R. Incorporation of polymeric nanoparticles into solid dosage forms. J Control Release 1999;57:115-125.
39. Bräuer L, Johl M, Börgermann J, et al. Detection and localization of the hydrophobic surfactant proteins B and C in human tear fluid and the human lacrimal system. Curr Eye Res 2007;32: 931-938.
40. Bräuer L, Paulsen FP. Tear film and ocular surface surfactants. J Epithel Biol Pharmacol 2008;1:62-67.
41. Duchêne D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev 1999; 36:29-40.
42. Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm 2000;197:1-11.
43. Ayaki M, Iwasawa A, Soda M, et al. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clin Ophthalmol 2010;4:1019-1024.
44. Thompson AM. Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol 2007;35:566-577.
45. Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy: J Human Pharmacol Drug Therapy 2001;21:35-59.
46. Boyd LB, Maynard MJ, Morgan-Linnell SK, et al. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009;53:229-234.